maxmuscle1
Board Rep
- Joined
- Apr 4, 2015
- Messages
- 25,533
- Reaction score
- 22,607
June 13, 2021 Latest Long rHGH News !!
Novo Nordisk’s Sogroya (somapacitan-beco) recently became the first long-acting GH to gain marketing authorisation in GHD for the treatment of adult patients in the US in 2020 and in the EU and Japan in 2021. Additionally, there are three more long-acting GHs in late-stage development (Phase II development or later), according to GlobalData’s pipeline products database, namely Ascendis Pharma’s TransCon hGH (lonapegsomatropin), Pfizer and OPKO Biologics’ somatrogon and Hanmi Pharmaceuticals’ efpegsomatropin.
The rapid uptake of long-acting growth hormones (GH) is set to shake up the growth hormone deficiency (GHD) market in the three major markets (3MM), namely the US, Germany and Japan. These therapies are projected to capture over 90% of the GHD market share by 2030, according to GlobalData’s recent ‘Growth Hormone Deficiency: Opportunity Assessment and Forecast to 2030’ report. The current leading GH therapeutics such as Novo Nordisk’s Norditropin (somatropin), Pfizer’s Genotropin (somatropin) and Eli Lilly’s Humatrope (somatropin) are likely to see their revenues plummet as a result.
**SOGROYA (somapacitan-beco) injection by Novo-Nordisk is supplied as a sterile, clear to slightly opalescent and colorless to slightly yellow solution for subcutaneous use in a single-patient-use prefilled pen with a deliverable volume of 10 mg per 1.5 mL / 6.7mg per 1cc to be administered subcutaneously. Max dose listed - 8mg . Monthly projected monthly wholesale price $23,900!! Omg!!
We may not be able to afford these new LrHgh : This tells me regular the Regular Brand Name HGH price will plummet and be available for a very affordable price, also any large buyer with pallets of rHGH close to expiration will sell super cheap.
Max
I already told doc, to contact me for any programs to get free or low price, coupons, samples(lmao)
Novo Nordisk’s Sogroya (somapacitan-beco) recently became the first long-acting GH to gain marketing authorisation in GHD for the treatment of adult patients in the US in 2020 and in the EU and Japan in 2021. Additionally, there are three more long-acting GHs in late-stage development (Phase II development or later), according to GlobalData’s pipeline products database, namely Ascendis Pharma’s TransCon hGH (lonapegsomatropin), Pfizer and OPKO Biologics’ somatrogon and Hanmi Pharmaceuticals’ efpegsomatropin.
The rapid uptake of long-acting growth hormones (GH) is set to shake up the growth hormone deficiency (GHD) market in the three major markets (3MM), namely the US, Germany and Japan. These therapies are projected to capture over 90% of the GHD market share by 2030, according to GlobalData’s recent ‘Growth Hormone Deficiency: Opportunity Assessment and Forecast to 2030’ report. The current leading GH therapeutics such as Novo Nordisk’s Norditropin (somatropin), Pfizer’s Genotropin (somatropin) and Eli Lilly’s Humatrope (somatropin) are likely to see their revenues plummet as a result.
**SOGROYA (somapacitan-beco) injection by Novo-Nordisk is supplied as a sterile, clear to slightly opalescent and colorless to slightly yellow solution for subcutaneous use in a single-patient-use prefilled pen with a deliverable volume of 10 mg per 1.5 mL / 6.7mg per 1cc to be administered subcutaneously. Max dose listed - 8mg . Monthly projected monthly wholesale price $23,900!! Omg!!
We may not be able to afford these new LrHgh : This tells me regular the Regular Brand Name HGH price will plummet and be available for a very affordable price, also any large buyer with pallets of rHGH close to expiration will sell super cheap.
Max





I already told doc, to contact me for any programs to get free or low price, coupons, samples(lmao)
